Navigation Links
Adeona Appoints George J. Brewer, M.D., Senior Vice President of Research & Development
Date:3/3/2011

ANN ARBOR, Mich., March 3, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today the appointment of George J. Brewer, M.D., as Senior Vice President of Research & Development.  Dr. Brewer joins the Adeona management team after serving as the Chairman of the Company's Scientific Advisory Board for seven years.

Dr. Brewer is the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan.  He was a member of the National Science Council's "Committee on Copper in Drinking Water" convened at the request of the Environmental Protection Agency in 2000 to consider the issue of what level of copper in drinking water could be considered "safe." Dr. Brewer has published over 500 scientific papers, several books and is the inventor of oral zinc therapy approved by the Food & Drug Administration (FDA) in 1997, now standard of care for chronic Wilson's disease.

"We are pleased that Dr. Brewer, a respected medical innovator and developer of zinc-based therapies over his career, accepted our offer to join Adeona's management team. As the Chairman of our Scientific Advisory Board, Dr. Brewer provided significant guidance with regard to our clinical development programs, and we look forward to his continued valuable contributions in his new role as Senior Vice President of Research & Development," stated James S. Kuo, M.D., M.B.A., Adeona's Chairman and CEO. "We also appreciate the condolences received following the passing of our colleague and friend, David Newsome. While this was an unexpected loss for the Company, we believe the appointment of Dr. Brewer positions our clinical development programs for continued advancement."

The study coordinators at the three clinical sites conducting Adeona's study evaluating reaZin™ (zinc cysteine) for the dietary management of Alzheimer's disease and mild cognitive impairment continue the follow-up appointments with the patients enrolled in this study. Adeona has also contracted a replacement clinical trial associate to monitor the study on behalf of the Company. Patients are scheduled to complete their final study visits by the end of March 2011. As previously announced, Adeona plans to present the results of its pivotal clinical trial in a poster presentation at the American Academy of Neurology Annual Meeting on April 14, 2011 at the Hawaii Convention Center in Honolulu, Hawaii. A concurrent press release will also be distributed.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "positions," "continue," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical studies and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, the availability of financial and other resources and the allocation of resources among different potential uses, a failure of our clinical trials to be completed on time or to achieve desired results, a failure of the new branding to achieve desired results, a failure of our clinical reference laboratory to continue to grow and achieve revenue or a failure by us or our strategic partners to successfully commercialize products and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona Announces HartLab Expansion Into Microbiology Testing Services
2. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
3. Adeona Announces Second Quarter 2010 Profitability and Achievements
4. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
5. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
6. Adeona to Hold Annual Shareholder Meeting
7. Adeona Announces Third Quarter 2010 Financial Results and Achievements
8. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
9. Adeona to Present at OneMedForum San Francisco 2011 Conference
10. Adeona to Host Investor Day on Zinc Deficiency in Alzheimers Disease
11. Adeona to Raise $4 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, ... report, "Cardiovascular Surgery Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
(Date:2/8/2016)... 2016  Labvantage Lx, a newcomer to the ... sexual enhancement product, EnduramenT. Setting a new standard ... a patented biomedical breakthrough molecule that promotes the ... responsible for many biological functions including erectile function. ... Forgoing the use of prescription medications, scientists working ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 2016 , ... Stephanie Hebert Insurance Agency, serving families of ... charity campaign. As part of their ongoing community involvement program, funds are now ... children deserve a voice, and in the spirit of neighbors helping neighbors in ...
(Date:2/8/2016)... , ... February 08, 2016 , ... A man who has struggled to quit smoking, ... Laser Therapy , was determined to find solutions to his problems – and he did. ... Digest is ready to introduce his breakthrough inventions to the world and better people's ...
(Date:2/8/2016)... York, NY (PRWEB) , ... February 08, 2016 , ... ... are too much to handle, you are not alone. According to the Center for ... include heart disease, stroke, type 2 diabetes and certain types of cancer, some of ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local ... the greater Venice, FL area, has initiated a fundraiser for a two year ... just four days after Christmas. To support this beautiful child who is facing ...
Breaking Medicine News(10 mins):